|Oct. 6, 2015|
ASHI Annual Meeting — Savannah, Georgia
Attendees of this year's annual meeting experienced a little "southern hospitality" and ample opportunities to learn about updates on regulatory and practice guidelines. In addition, many areas relevant to the histocompatibility and immunogenetics laboratory and the transplant community at large were discussed. The meeting included abundant opportunities to network with other attendees from the following countries: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Costa Rica, Denmark, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Republic of Korea, Lebanon, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Qatar, Saudi Arabia, Singapore, Spain, Switzerland, United Arab Emirates, United Kingdom and the United States. More
New board appointment
The ASHI Board of Directors appointed John Schmitz, Ph.D., D(ABHI), from UNC Hospitals to the board for a one-year appointment replacing Dr. Gautreaux who moved into the president-elect position.
ASHI 5K Fun Run/Walk
ASHI's 3rd Annual Run for a Life 5K Fun Run/1 Mile Walk took place on Wednesday, Sept. 30 and raised $2,350 which will be donated to the local OPO, LifeLink.
This event was sponsored by:
2015 best case study
This case study received the highest ranking score and receives a $200 award.
OR15 De Novo Development of DSA Following Human Lung Transplantation is Associated with Changes on Circulating Micro-RNA Involved in T and B Cell Regulation and Fibrogenesis
Washington University School of Medicine, St. Louis, MOMore
2015 poster awards
All posters were considered for awards in four categories: Most Innovative, Most Clinically Relevant, People's Choice and President's Choice. The winner in each category receives a $100 award.
P057 How Masked High-titer Hla Antibodies Change In Highly Sensitized Patients After Hematopoietic Stem Cell Transplantation (Hsct)
Michiko Taniguchi, City of Hope Medical Center, Duarte, CA
Most Clinically Relevant
P108 Phased Full Length Smrt Sequencing Of Hla-dpb1
Kathrin Lang, DKMS Life Science Lab, Dresden, Germany
P081 Optimization Of Solid Phase And Flow Cytometry Crossmatch Assays Through The Use Of Dtt Treated Patient Sera
Katharine Spanjer, ClinImmune Labs, Aurora, CO
P111 Unexpected Association Of Reduced Activating Kir-hla Genotypes With Autoimmune Vogt-koyanagi-harada Disease
Raja Rajalingam, Immunogenetics and Transplantation Laboratory, University of California San Francisco, San Francisco, CA More
Tech forum question of the quarter
Each quarter, the Technologist’s Affairs committee will be posting a question to ASHI technologists. Please go to the Tech Forum to submit your comments.
Question: What did you like best or get the most from at the ASHI meeting, and why?
My answer: I have been to several ASHI meetings over my 28 years in HLA, and each meeting brings something new to me. When I went to my first meeting or two, I wondered what language these people were speaking. Now I understand more at each meeting and enjoy learning what other labs are doing as well as some of the more scientific data. The thing I got most from this meeting, however, was meeting new people. I met people from ASHI who I have talked to via email for years, but had never met. Kathy, Melissa and Cecilia are invaluable to ASHI and it was great having a face to the name. I also met other techs who I wouldn't have met such as the ladies I met from Edmonton, Canada. I can't remember all the names, but Sharon and Karen and the rest of the group were wonderful to talk to and get a snippet of life in Canada. I was also able to see people who I had met before, but hadn't seen since the last meeting. All in all, I would say I got the most from meeting new people and the sessions. It was a great meeting and I look forward to hear what you have to say, so join the conversation.
Jody Jennemann BS, MT (ASCP), CHS (ABHI)
Vice Chair Technologist's AffairsMore
OPTN/UNOS Policy and Bylaw Proposals
Distributed for Public Comment
Aug. 14, 2015
This document contains twelve proposals being offered for public comment. These proposals were developed by OPTN/UNOS committees. When the public comment period ends on Oct. 14, 2015, each sponsoring committee will review the feedback it received and consider modifications to the original proposals. The OPTN/UNOS Board of Directors may then review and vote on these proposals at its meeting on Dec. 1-2, 2015.
Please click on the following link to provide your comments on these proposals: http://optn.transplant.hrsa.gov/governance/public-comment/.
You may also continue to send general feedback to firstname.lastname@example.org.
Please submit all comments no later than Oct. 14, 2015. For general questions about the proposals, please contact your Regional Administrator at 804-782-4800.
We welcome your feedback on these proposals and other aspects of the public comment process as we continue to improve the way that we communicate with the community.
Thank you in advance for your careful review and feedback on these proposals. More